Compare LFMD & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | SLGL |
|---|---|---|
| Founded | 1994 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.1M | 254.1M |
| IPO Year | 2012 | 2016 |
| Metric | LFMD | SLGL |
|---|---|---|
| Price | $3.14 | $77.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $9.14 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 1.0M | 42.4K |
| Earning Date | 05-06-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 141.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,468,578.00 | N/A |
| Revenue This Year | $17.52 | N/A |
| Revenue Next Year | $18.73 | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.79 | N/A |
| 52 Week Low | $2.60 | $20.10 |
| 52 Week High | $7.32 | $97.97 |
| Indicator | LFMD | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 45.94 |
| Support Level | $3.00 | $67.89 |
| Resistance Level | $3.41 | $81.18 |
| Average True Range (ATR) | 0.25 | 6.36 |
| MACD | 0.00 | -0.89 |
| Stochastic Oscillator | 14.20 | 33.93 |
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.